Microsatellite Instability: From the Implementation of the Detection to a Prognostic and Predictive Role in Cancers

Microsatellite instability (MSI) has been identified in several tumors arising from either germline or somatic aberration. The presence of MSI in cancer predicts the sensitivity to immune checkpoint inhibitors (ICIs), particularly PD1/PD-L1 inhibitors. To date, the predictive role of MSI is currently used in the selection of colorectal cancer patients for immunotherapy; moreover, the expansion of clinical trials into other cancer types may elucidate the predictive value of MSI for non-colorectal tumors. In clinical practice, several assays are used for MSI testing, including immunohistochemistry (IHC), polymerase chain reaction (PCR) and next-generation sequencing (NGS). In this review, we provide an overview of MSI in various cancer types, highlighting its potential predictive/prognostic role and the clinical trials performed. Finally, we focus on the comparison data between the different assays used to detect MSI in clinical practice.

[1]  M. Caraglia,et al.  Microsatellite Status Detection in Gastrointestinal Cancers: PCR/NGS Is Mandatory in Negative/Patchy MMR Immunohistochemistry , 2022, Cancers.

[2]  Tao Wu,et al.  Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities , 2022, Frontiers in Immunology.

[3]  P. Peltomäki,et al.  Testing for Lynch Syndrome in Endometrial Carcinoma: From Universal to Age-Selective MLH1 Methylation Analysis , 2022, Cancers.

[4]  Edel del Barco Morillo,et al.  Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis , 2022, Biomedicines.

[5]  Yi Zhang,et al.  Correlation of mismatch repair deficiency with clinicopathological features and programmed death-ligand 1 expression in thyroid carcinoma , 2022, Endocrine.

[6]  A. Italiano,et al.  Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Tinker,et al.  Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study , 2022, Journal for ImmunoTherapy of Cancer.

[8]  A. Cimadamore,et al.  An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT , 2021, International journal of molecular sciences.

[9]  Fenghua Wang,et al.  The Impact of Mismatch Repair Status on Prognosis of Patients With Gastric Cancer: A Multicenter Analysis , 2021, Frontiers in Oncology.

[10]  G. Turashvili,et al.  EPM2AIP1 Immunohistochemistry Can Be Used as Surrogate Testing for MLH1 Promoter Methylation in Endometrial Cancer , 2021, The American journal of surgical pathology.

[11]  K. Schmid,et al.  The prevalence of DNA microsatellite instability in anaplastic thyroid carcinoma – systematic review and discussion of current therapeutic options , 2021, Contemporary oncology.

[12]  E. Van Cutsem,et al.  First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Xiang-Shang Hu,et al.  Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment , 2021, OncoTargets and therapy.

[14]  T. Iijima,et al.  Clinicopathological features of sporadic MSI colorectal cancer and Lynch syndrome: a single-center retrospective cohort study , 2021, International Journal of Clinical Oncology.

[15]  E. Huang,et al.  Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis. , 2021, Gynecologic oncology.

[16]  V. Mazzaferro,et al.  TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study , 2021, Cancers.

[17]  M. Jin,et al.  Microsatellite instability and Epstein-Barr virus combined with PD-L1 could serve as a potential strategy for predicting the prognosis and efficacy of postoperative chemotherapy in gastric cancer , 2021, PeerJ.

[18]  M. Invernizzi,et al.  Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization , 2021, Cancer cell international.

[19]  E. Van Cutsem,et al.  Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. , 2021, The Lancet. Oncology.

[20]  Y. Bang,et al.  Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. , 2021, JAMA oncology.

[21]  Qun Zhao,et al.  Amplification of the human epidermal growth factor receptor 2 (HER2) gene is associated with a microsatellite stable status in Chinese gastric cancer patients. , 2021, Journal of gastrointestinal oncology.

[22]  A. Ristimäki,et al.  Detection of microsatellite instability with Idylla MSI assay in colorectal and endometrial cancer , 2021, Virchows Archiv.

[23]  Yanlin Huang,et al.  A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer , 2021, BMC cancer.

[24]  Biao Yang,et al.  Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors , 2021, Frontiers in Oncology.

[25]  T. Buhl,et al.  Managing Difficulties of Microsatellite Instability Testing in Endometrial Cancer-Limitations and Advantages of Four Different PCR-Based Approaches , 2021, Cancers.

[26]  M. Erçin,et al.  Investigation of the relationship between immune checkpoints and mismatch repair deficiency in recurrent and nonrecurrent glioblastoma , 2021, Turkish journal of medical sciences.

[27]  M. Buisine,et al.  Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors , 2021, Cancers.

[28]  K. Claes,et al.  Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer , 2021, Scientific Reports.

[29]  W. Horninger,et al.  Lynch Syndrome: Its Impact on Urothelial Carcinoma , 2021, International journal of molecular sciences.

[30]  N. Guevara,et al.  From biomarkers to therapeutic targets: the promise of PD-L1 in thyroid autoimmunity and cancer , 2021, Theranostics.

[31]  A. Kurian,et al.  Prevalence of Lynch syndrome in women with mismatch repair‐deficient ovarian cancer , 2020, Cancer medicine.

[32]  E. Montagna,et al.  Endometrial cancer: a genetic point of view , 2020, Translational cancer research.

[33]  Z. Rosenwaks,et al.  Gynecological Cancers Caused by Deficient Mismatch Repair and Microsatellite Instability , 2020, Cancers.

[34]  Mary Jones,et al.  Idylla microsatellite instability assay versus mismatch repair immunohistochemistry: a retrospective comparison in gastric adenocarcinoma , 2020, Journal of Clinical Pathology.

[35]  A. Leroux,et al.  Evaluation of 3 molecular-based assays for microsatellite instability detection in formalin-fixed tissues of patients with endometrial and colorectal cancers , 2020, Scientific Reports.

[36]  Steven C. Smith,et al.  Universal Mismatch Repair Protein Screening in Upper Tract Urothelial Carcinoma. , 2020, American journal of clinical pathology.

[37]  M. Salto‐Tellez,et al.  Identifying mismatch repair‐deficient colon cancer: near‐perfect concordance between immunohistochemistry and microsatellite instability testing in a large, population‐based series , 2020, Histopathology.

[38]  W. Guan,et al.  The Better Survival of MSI Subtype Is Associated With the Oxidative Stress Related Pathways in Gastric Cancer , 2020, Frontiers in Oncology.

[39]  J. Calderaro,et al.  Detection of microsatellite instability in a panel of solid tumours with the Idylla MSI Test using extracted DNA , 2020, Journal of Clinical Pathology.

[40]  M. Guida,et al.  TCGA Classification of Endometrial Cancer: the Place of Carcinosarcoma , 2020, Pathology & Oncology Research.

[41]  M. Kloor,et al.  Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: a prospective cohort study , 2020, BMC Cancer.

[42]  K. Bilguvar,et al.  Whole exome sequencing-based analysis to identify DNA damage repair deficiency as a major contributor to gliomagenesis in adult diffuse gliomas. , 2020, Journal of neurosurgery.

[43]  Michael Friberg Bruun Nielsen,et al.  Frequency of mismatch repair deficiency in pancreatic ductal adenocarcinoma. , 2020, Pathology, research and practice.

[44]  S. Dogan,et al.  Dissecting Anaplastic Thyroid Carcinoma (ATC): A Comprehensive Clinical, histologic, Immunophenotypic, and Molecular Study of 360 Cases. , 2020, Thyroid : official journal of the American Thyroid Association.

[45]  G. Sauter,et al.  MMR deficiency in urothelial carcinoma of the bladder presents with temporal and spatial homogeneity throughout the tumor mass. , 2020, Urologic oncology.

[46]  C. Tournigand,et al.  [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment]. , 2020 .

[47]  Hui Luo,et al.  Microsatellite instability: a review of what the oncologist should know , 2020, Cancer Cell International.

[48]  Masafumi Nakamura,et al.  Microsatellite instability in Japanese female patients with triple-negative breast cancer , 2020, Breast Cancer.

[49]  L. Diaz,et al.  Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  R. Goldberg,et al.  Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer. , 2019, The oncologist.

[51]  D. Jäger,et al.  Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164 , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  S. Kyo,et al.  Relationship between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future , 2019, International journal of molecular sciences.

[53]  G. Berardinelli,et al.  EP1.04-11 Frequency of Microsatellite Instability (MSI) in Brazilian TKI Non-Treatable Non-Small Cell Lung Cancer (NSCLC) Patients , 2019, Journal of Thoracic Oncology.

[54]  O. Hino,et al.  Usefulness of immunohistochemistry for mismatch repair protein and microsatellite instability examination in adenocarcinoma and background endometrium of sporadic endometrial cancer cases , 2019, The journal of obstetrics and gynaecology research.

[55]  R. Kurzrock,et al.  Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD‐L1 expression in cancer patients , 2019, International journal of cancer.

[56]  M. Wing,et al.  Detection of Microsatellite Instability Biomarkers via Next-Generation Sequencing. , 2019, Methods in molecular biology.

[57]  H. Marusawa,et al.  Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers , 2019, Journal of Gastroenterology.

[58]  L. Looi,et al.  Screening for microsatellite instability in colorectal carcinoma: Practical utility of immunohistochemistry and PCR with fragment analysis in a diagnostic histopathology setting. , 2019, The Malaysian journal of pathology.

[59]  Aung Ko Win,et al.  Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database , 2019, Genetics in Medicine.

[60]  U. Ladabaum,et al.  Comparison of Universal Versus Age-Restricted Screening of Colorectal Tumors for Lynch Syndrome Using Mismatch Repair Immunohistochemistry , 2019, Annals of Internal Medicine.

[61]  E. Antonarakis,et al.  Clinical implications of mismatch repair deficiency in prostate cancer. , 2019, Future oncology.

[62]  E. Alexander,et al.  Clinicopathologic Features of Mismatch Repair-Deficient Anaplastic Thyroid Carcinomas. , 2019, Thyroid : official journal of the American Thyroid Association.

[63]  D. Kerr,et al.  Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features , 2019, International journal of cancer.

[64]  Y. Xi,et al.  Screening of MSI detection loci and their heterogeneity in East Asian colorectal cancer patients , 2019, Cancer medicine.

[65]  Charu Aggarwal,et al.  Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. , 2019, The Lancet. Respiratory medicine.

[66]  A. Duval,et al.  Pancreatic ductal adenocarcinoma harboring microsatellite instability / DNA mismatch repair deficiency. Towards personalized medicine. , 2019, Surgical oncology.

[67]  F. Kastrinos,et al.  Tumor Testing for Microsatellite Instability to Identify Lynch Syndrome: New Insights Into an Old Diagnostic Strategy. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  Ahmet Zehir,et al.  Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  R. Harun,et al.  Microsatellite Instability and Altered Expressions of MLH1 and MSH2 in Gastric Cancer , 2019, Asian Pacific journal of cancer prevention : APJCP.

[70]  S. Kamel‐Reid,et al.  Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation , 2018, The journal of pathology. Clinical research.

[71]  Hoguen Kim,et al.  Microsatellite instability test using peptide nucleic acid probe-mediated melting point analysis: a comparison study , 2018, BMC Cancer.

[72]  V. Vaira,et al.  Mismatch Repair Protein Loss as a Prognostic and Predictive Biomarker in Breast Cancers Regardless of Microsatellite Instability , 2018, JNCI cancer spectrum.

[73]  W. Frankel,et al.  Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency , 2018, Modern Pathology.

[74]  R. Yantiss,et al.  Assessing colorectal cancer mismatch repair status in the modern era: a survey of current practices and re-evaluation of the role of microsatellite instability testing , 2018, Modern Pathology.

[75]  R. Reis,et al.  Advantage of HSP110 (T17) marker inclusion for microsatellite instability (MSI) detection in colorectal cancer patients , 2018, Oncotarget.

[76]  H. Cathro,et al.  Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas , 2018, The American journal of surgical pathology.

[77]  C. Gilks,et al.  Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups , 2018, The American journal of surgical pathology.

[78]  I. Ladas,et al.  Enhanced detection of microsatellite instability using pre-PCR elimination of wild-type DNA homo-polymers in tissue and liquid biopsies , 2018, Nucleic acids research.

[79]  S. Loi,et al.  Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer , 2018, Clinical Cancer Research.

[80]  F. Roviello,et al.  Meta‐analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer , 2018, The British journal of surgery.

[81]  S. Urakami,et al.  Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening , 2018, International journal of urology : official journal of the Japanese Urological Association.

[82]  C. Moskaluk,et al.  The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma , 2018, The American journal of surgical pathology.

[83]  C. Iacobuzio-Donahue,et al.  Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations , 2018, Clinical Cancer Research.

[84]  M. Sawyer,et al.  Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  Jinghong Xu,et al.  A Novel and Reliable Method to Detect Microsatellite Instability in Colorectal Cancer by Next-Generation Sequencing. , 2017, The Journal of molecular diagnostics : JMD.

[86]  A. Duval,et al.  Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas. , 2017, Gastroenterology.

[87]  Huamin Wang,et al.  Clinical and Genetic Implications of DNA Mismatch Repair Deficiency in Patients With Pancreatic Ductal Adenocarcinoma , 2017, JAMA surgery.

[88]  J. Eshleman,et al.  MSH2 Loss in Primary Prostate Cancer , 2017, Clinical Cancer Research.

[89]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[90]  P. Møller,et al.  Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database , 2017, Gut.

[91]  Tae Won Kim,et al.  Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. , 2017 .

[92]  Ali Bashashati,et al.  Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes , 2017, Nature Genetics.

[93]  R. Broaddus,et al.  Universal Point of Care Testing for Lynch Syndrome in Patients with Upper Tract Urothelial Carcinoma , 2017, The Journal of urology.

[94]  Joonhong Park,et al.  Evaluation of the Three Customized MSI Panels to Improve the Detection of Microsatellite Instability in Gastric Cancer. , 2017, Clinical laboratory.

[95]  W. Frankel,et al.  Molecular genetics of microsatellite-unstable colorectal cancer for pathologists , 2017, Diagnostic Pathology.

[96]  M. Rugge,et al.  Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial , 2017, JAMA oncology.

[97]  Lauren L. Ritterhouse,et al.  Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression , 2017, Oncoimmunology.

[98]  Russell Bonneville,et al.  Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS , 2016, Oncotarget.

[99]  C. Röcken,et al.  Clinicopathologic Characteristics of Microsatellite Instable Gastric Carcinomas Revisited: Urgent Need for Standardization , 2016, Applied immunohistochemistry & molecular morphology : AIMM.

[100]  G. E. Carpagnano,et al.  New panel of microsatellite alterations detectable in the EBC for lung cancer prognosis , 2016, Journal of Cancer.

[101]  P. Park,et al.  A molecular portrait of microsatellite instability across multiple cancers , 2016, Nature Communications.

[102]  Jay Shendure,et al.  Classification and characterization of microsatellite instability across 18 cancer types , 2016, Nature Medicine.

[103]  J. Kopecký,et al.  Microsatellite instability as a predictive factor for immunotherapy in malignant melanoma. , 2016, Medical hypotheses.

[104]  K. Patel,et al.  Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability , 2016, The American journal of surgical pathology.

[105]  M. Kloor,et al.  Microsatellite instability in pulmonary adenocarcinomas: a comprehensive study of 480 cases , 2016, Virchows Archiv.

[106]  James R. Eshleman,et al.  Microsatellite Instability as a Biomarker for PD-1 Blockade , 2016, Clinical Cancer Research.

[107]  Hiromu Suzuki,et al.  Clinicopathological and molecular alterations in early gastric cancers with the microsatellite instability‐high phenotype , 2015, International journal of cancer.

[108]  P. Wei,et al.  Immunohistochemistry and microsatellite instability analysis in molecular subtyping of colorectal carcinoma based on mismatch repair competency. , 2015, International journal of clinical and experimental medicine.

[109]  K. Kinzler,et al.  The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints , 2015, Journal of Immunotherapy for Cancer.

[110]  L. Clipson,et al.  Improved Detection of Microsatellite Instability in Early Colorectal Lesions , 2015, PloS one.

[111]  S. Kalloger,et al.  Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma , 2015, Modern Pathology.

[112]  A. Talhouk,et al.  Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. , 2015, Gynecologic oncology.

[113]  Jason G. Jin,et al.  Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes , 2015, Nature Medicine.

[114]  G. Smailytė,et al.  Endometrial cancer and microsatellite instability status , 2014, Open medicine.

[115]  Rahul Bhagat,et al.  Microsatellite instability, promoter methylation and protein expression of the DNA mismatch repair genes in epithelial ovarian cancer. , 2014, Genomics.

[116]  Ming Yu,et al.  Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer , 2014, Nature Communications.

[117]  Wei Zhang.  TCGA divides gastric cancer into four molecular subtypes: implications for individualized therapeutics , 2014, Chinese journal of cancer.

[118]  Colin C Pritchard,et al.  Microsatellite instability detection by next generation sequencing. , 2014, Clinical chemistry.

[119]  I. Nagtegaal,et al.  Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies , 2014, Clinical Cancer Research.

[120]  Kai Ye,et al.  MSIsensor: microsatellite instability detection using paired tumor-normal sequence data , 2014, Bioinform..

[121]  T. Sellers,et al.  Association between IHC and MSI testing to identify mismatch repair-deficient patients with ovarian cancer. , 2014, Genetic testing and molecular biomarkers.

[122]  Peter J. Park,et al.  The Landscape of Microsatellite Instability in Colorectal and Endometrial Cancer Genomes , 2013, Cell.

[123]  R. Reis,et al.  Optimization of a pentaplex panel for MSI analysis without control DNA in a Brazilian population: correlation with ancestry markers , 2013, European Journal of Human Genetics.

[124]  Reiko Nishihara,et al.  Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. , 2013, Journal of the National Cancer Institute.

[125]  D. Lambrechts,et al.  Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab , 2013, Clinical Cancer Research.

[126]  Yuheng Lu,et al.  A Novel Approach for Characterizing Microsatellite Instability in Cancer Cells , 2013, PloS one.

[127]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[128]  P. Goodfellow,et al.  Frequent mutations in the RPL22 gene and its clinical and functional implications. , 2013, Gynecologic oncology.

[129]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[130]  Hoguen Kim,et al.  Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5‐FU based chemotherapy after R0 resection , 2012, International journal of cancer.

[131]  Colin C Pritchard,et al.  ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. , 2012, The Journal of molecular diagnostics : JMD.

[132]  Hiromu Suzuki,et al.  Interrelationship between microsatellite instability and microRNA in gastrointestinal cancer. , 2012, World journal of gastroenterology.

[133]  K. Aittomäki,et al.  Breast carcinoma and Lynch syndrome: molecular analysis of tumors arising in mutation carriers, non-carriers, and sporadic cases , 2012, Breast Cancer Research.

[134]  Axel Benner,et al.  Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study. , 2012, The Lancet. Oncology.

[135]  P. Hudler.  Genetic Aspects of Gastric Cancer Instability , 2012, TheScientificWorldJournal.

[136]  J. Weitzel,et al.  Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[137]  A. Karnezis,et al.  Ovarian Endometrioid Adenocarcinoma: Incidence and Clinical Significance of the Morphologic and Immunohistochemical Markers of Mismatch Repair Protein Defects and Tumor Microsatellite Instability , 2012, The American journal of surgical pathology.

[138]  A. N. Bartley,et al.  Identification of Cancer Patients with Lynch Syndrome: Clinically Significant Discordances and Problems in Tissue-Based Mismatch Repair Testing , 2011, Cancer Prevention Research.

[139]  P. Gibbs,et al.  Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer , 2011, Cancer.

[140]  N. Wentzensen,et al.  Frequency of mismatch repair deficiency in ovarian cancer: a systematic review This article is a US Government work and, as such, is in the public domain of the United States of America. , 2011, International journal of cancer.

[141]  J. Horbańczuk,et al.  The use of microsatellite polymorphism in genetic mapping of the ostrich (Struthio camelus) , 2011, Molecular Biology Reports.

[142]  Matej Horvat,et al.  Microsatellite instability in colorectal cancer , 2011, Radiology and oncology.

[143]  F. Roviello,et al.  Oncogenic mutations in gastric cancer with microsatellite instability. , 2011, European journal of cancer.

[144]  M. Perucho,et al.  Double strand break repair components are frequent targets of microsatellite instability in endometrial cancer. , 2010, European journal of cancer.

[145]  A. de la Chapelle,et al.  Clinical relevance of microsatellite instability in colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[146]  H. Hampel.  Point: justification for Lynch syndrome screening among all patients with newly diagnosed colorectal cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[147]  Ajay Goel,et al.  Microsatellite instability in colorectal cancer. , 2010, Gastroenterology.

[148]  D. Aoki,et al.  Analysis of candidate target genes for mononucleotide repeat mutation in microsatellite instability-high (MSI-H) endometrial cancer. , 2009, International journal of oncology.

[149]  S. Lipkin,et al.  Epigenetic repression of DNA mismatch repair by inflammation and hypoxia in inflammatory bowel disease-associated colorectal cancer. , 2009, Cancer research.

[150]  I. Wistuba,et al.  Allelotyping, Microsatellite Instability, and BRAF Mutation Analyses in Common and Atypical Melanocytic Nevi and Primary Cutaneous Melanomas , 2009, The American Journal of dermatopathology.

[151]  Mari Mino-Kenudson,et al.  Deficient DNA mismatch repair is common in Lynch syndrome-associated colorectal adenomas. , 2009, The Journal of molecular diagnostics : JMD.

[152]  J. Cubiella,et al.  The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. , 2009, European journal of cancer.

[153]  Poonam K Sharma,et al.  Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer , 2009, Familial Cancer.

[154]  K. Jensen,et al.  Microsatellite Instability and Mismatch Repair Protein Defects in Ovarian Epithelial Neoplasms in Patients 50 Years of Age and Younger , 2008, The American journal of surgical pathology.

[155]  P. Goodfellow,et al.  Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[156]  D. Rosen,et al.  Immunohistochemical staining of hMLH1 and hMSH2 reflects microsatellite instability status in ovarian carcinoma , 2006, Modern Pathology.

[157]  S. Pena,et al.  The Genetic Structure of Human Populations Studied Through Short Insertion‐Deletion Polymorphisms , 2006, Annals of human genetics.

[158]  M. Perucho,et al.  The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer , 2006, International journal of cancer.

[159]  Kathleen M Murphy,et al.  [Clinicopathological features and types of microsatellite instability in 1394 patients with colorectal cancer]. , 2020, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.

[160]  V. Agnese,et al.  Patterns of genomic instability in gastric cancer: clinical implications and perspectives. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[161]  J. Jiricny.  The multifaceted mismatch-repair system , 2006, Nature Reviews Molecular Cell Biology.

[162]  E. Oki,et al.  Two modes of microsatellite instability in human cancer: differential connection of defective DNA mismatch repair to dinucleotide repeat instability , 2005, Nucleic acids research.

[163]  J. Woosley,et al.  Microsatellite Instability Testing in Colorectal Carcinoma: Choice of Markers Affects Sensitivity of Detection of Mismatch Repair–Deficient Tumors , 2005, Clinical Cancer Research.

[164]  A. Ochiai,et al.  Microsatellite instability and protein expression of the DNA mismatch repair gene, hMLH1, of lung cancer in chromate‐exposed workers , 2005, Molecular carcinogenesis.

[165]  A. Sepulveda,et al.  Microsatellite instability and DNA mismatch repair deficiency testing in hereditary and sporadic gastrointestinal cancers. , 2005, Clinics in laboratory medicine.

[166]  R. Broaddus,et al.  Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. , 2004, Human pathology.

[167]  Fengzhu Sun,et al.  The relationship between microsatellite slippage mutation rate and the number of repeat units. , 2003, Molecular biology and evolution.

[168]  A. Hartmann,et al.  Microsatellite instability at chromosome 8p in non-small cell lung cancer is associated with lymph node metastasis and squamous differentiation. , 2003, International journal of oncology.

[169]  Hoguen Kim,et al.  Chromosomal imbalances in the colorectal carcinomas with microsatellite instability. , 2003, The American journal of pathology.

[170]  F. Paraf,et al.  Microsatellite instability in colorectal carcinoma. The comparison of immunohistochemistry and molecular biology suggests a role for hMSH6 [correction of hMLH6] immunostaining. , 2003, Archives of pathology & laboratory medicine.

[171]  A. Duval,et al.  Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. , 2002, Gastroenterology.

[172]  A. Millar,et al.  Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability. , 2002, Cancer research.

[173]  W. Stolz,et al.  Microsatellite instability in malignant melanomas. , 2001, Acta dermato-venereologica.

[174]  J. Varley,et al.  Immunohistochemical analysis of expression and allelotype of mismatch repair genes (hMLH1 and hMSH2) in bladder cancer , 2001, British Journal of Cancer.

[175]  J. Chang,et al.  Correlation of genetic instability with mismatch repair protein expression and p53 mutations in non-small cell lung cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[176]  C. Bartoli,et al.  Detection of microsatellite alterations in the spectrum of melanocytic nevi in patients with or without individual or family history of melanoma , 2000, International journal of cancer.

[177]  I. Jacobs,et al.  Frequency and prognostic impact of microsatellite instability in a large population-based study of endometrial carcinomas. , 2000, Cancer research.

[178]  A. Simpson,et al.  Microsatellite instability in tumors as a model to study the process of microsatellite mutations. , 2000, Human molecular genetics.

[179]  M. Broggini,et al.  CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. , 1999, Genes, chromosomes & cancer.

[180]  N. Roodi,et al.  Microsatellite instability and loss of heterozygosity in breast cancer. , 1994, Cancer research.

[181]  S N Thibodeau,et al.  Microsatellite instability in cancer of the proximal colon. , 1993, Science.

[182]  Kyoung-Mee Kim,et al.  MMR protein immunohistochemistry and microsatellite instability in gastric cancers. , 2019, Pathology.

[183]  David R. Jones,et al.  Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. , 2018, Cancer discovery.

[184]  B. Melosky,et al.  Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications. , 2018, Archives of pathology & laboratory medicine.

[185]  S. Ni,et al.  Clinicopathological features and prognostic value of mismatch repair protein deficiency in gastric cancer. , 2018, International journal of clinical and experimental pathology.

[186]  J. McKenney,et al.  Upper tract urothelial carcinomas: frequency of association with mismatch repair protein loss and lynch syndrome , 2017, Modern Pathology.

[187]  Suet Yi Leung,et al.  Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1 , 2009, Nature Genetics.

[188]  J. Boyd,et al.  Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer. , 2008, Human pathology.

[189]  C. Compton,et al.  The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. , 2007, Gastroenterology.

[190]  J. Barrett,et al.  Testing guidelines for hereditary non-polyposis colorectal cancer , 2004, Nature Reviews Cancer.

[191]  M. Stratton,et al.  Mutations of BRAF and KRAS in gastric cancer and their association with microsatellite instability , 2004, International journal of cancer.

[192]  J. Jiricny,et al.  High-frequency microsatellite instability is associated with defective DNA mismatch repair in human melanoma. , 2002, The Journal of investigative dermatology.

[193]  P. Pérez-Segura,et al.  Microsatellite instability correlates with negative expression of estrogen and progesterone receptors in sporadic breast cancer. , 2000, Teratogenesis, carcinogenesis, and mutagenesis.